Antiepileptic drugs and risk factors of cardiovascular disease

WANG Xinxin; LU Qinchi

doi:10.12022/jnnr.2016-0021

PDF(1387 KB)

Journal of Neurology and Neurorehabilitation ›› 2016, Vol. 12 ›› Issue (1) : 36-40. DOI: 10.12022/jnnr.2016-0021

Review

Antiepileptic drugs and risk factors of cardiovascular disease

WANG Xinxin, LU Qinchi

Author information +

History +

Abstract

There is a reciprocal causal relationship between epilepsy and cardiovascular disease (CVD), which means that epilepsy may increase the incidence rate and mortality of CVD, while the CVD may induce the sudden unexpected death in epilepsy. Different antiepileptic drugs have different effects on the risk factors of CVD including body weight, insulin resistance, metabolic syndrome, serum uric acid level, carotid artery intima-media thickness and markers of oxidative stress. In view of the fact that some antiepileptic drugs may increase or reduce the risk of occurrence of CVD, therefore, in individualized antiepileptic therapy, appropriate antiepileptic drugs should be selected for patients with high risk of CVD, meanwhile, the rational use of drugs which can reduce the risk of CVD is recommended.

Key words

Epilepsy / Sudden unexpected death in epilepsy / Antiepileptic drugs / Cardiovascular disease / Risk factors

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

WANG Xinxin, LU Qinchi. Antiepileptic drugs and risk factors of cardiovascular disease[J]. Journal of Neurology and Neurorehabilitation. 2016, 12(1): 36-40 https://doi.org/10.12022/jnnr.2016-0021

References

[1] WU Y, LIU D, SONG Z. Neuronal networks and energy bursts in epilepsy[J]. Neuroscience, 2015(287):175-186.
[2] CONRAD J, PAWLOWSKI M, DOGAN M, et al. Seizures after cerebrovascular events: risk factors and clinical features[J]. Seizure, 2013, 22(4):275-282.
[3] ATHYROS V G, KAKAFIKA A I, PAPAGEORGIOU A A, et al. Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors[J]. Nutr Metab Cardiovasc Dis, 2011, 21(3):213-221.
[4] LAMBERTS R J, BLOM M T, WASSENAAR M, et al. Sudden cardiac arrest in people with epilepsy in the community: Circumstances and risk factors[J]. Neurology, 2015, 85(3):212-218.
[5] BROTHERSTONE R, BLACKHALL B, MCLELLAN A. Lengthening of corrected QT during epileptic seizures[J]. Epilepsia, 2010, 51(2):221-232.
[6] GOLDMAN A M, GLASSCOCK E, YOO J, et al. Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained death[J]. Sci Transl Med, 2009, 1(2):2ra6.
[7] JEHI L, SCHUELE S. Sudden death in epilepsy Where is the “heart” of the problem?[J]. Neurology, 2015, 85(3):208-209.
[8] TOLSTYKH G P, CAVAZOS J E. Potential mechanisms of sudden unexpected death in epilepsy[J]. Epilepsy Behav, 2013, 26(3):410-414.
[9] LA ROVERE M T. Baroreflex sensitivity as a new marker for risk stratification[J]. Z Kardiol, 2000(89 Suppl 3):44-50.
[10] AHIRWAR A K, JAIN A, SINGH A, et al. The study of markers of endothelial dysfunction in metabolic syndrome[J]. Horm Mol Biol Clin Investig, 2015, 24(3):131-136.
[11] TSOULI S G, LIBEROPOULOS E N, MIKHAILIDIS D P, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?[J]. Metabolism, 2006, 55(10):1293-1301.
[12] PATETSIOS P, RODINO W, WISSELINK W, et al. Identification of uric acid in aortic aneurysms and atherosclerotic artery[J]. Ann N Y Acad Sci, 1996(800):243-245.
[13] SIEFERT S A, SARKAR R. Matrix metalloproteinases in vascular physiology and disease[J]. Vascular, 2012, 20(4):210-216.
[14] PYLVÄNEN V, KNIP M, PAKARINEN A J, et al. Fasting serum insulin and lipid levels in men with epilepsy[J]. Neurology, 2003, 60(4):571-574.
[15] SVALHEIM S, LUEF G, RAUCHENZAUNER M, et al. Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine[J]. Acta Neurol Scand Suppl, 2010(190):30-33.
[16] ZENG K, WANG X, XI Z, et al. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients[J]. Clin Neurol Neurosurg, 2010, 112(4):291-295.
[17] LUEF G, RAUCHENZAUNER M, WALDMANN M, et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment[J]. Epilepsy Res, 2009, 86(1):42-47.
[18] RING H A, HELLER A J, MARSHALL W J, et al. Plasma uric acid in patients receiving anticonvulsant monotherapy[J]. Epilepsy Res, 1991, 8(3):241-244.
[19] FILIPPATOS T D, KIORTSIS D N, LIBEROPOULOS E N, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study[J]. Curr Med Res Opin, 2005, 21(12):1997-2006.
[20] ATHYROS V G, MIKHAILIDIS D P, LIBEROPOULOS E N, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study[J]. Nephrol Dial Transplant, 2007, 22(1):118-127.
[21] DEROSA G, MAFFIOLI P. Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients[J]. Expert Rev Cardiovasc Ther, 2010, 8(6):835-843.
[22] DASKALOPOULOU S S, ATHYROS V G, ELISAF M, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study[J]. Kidney Int, 2004, 66(4):1714-1715.
[23] YUEN A W, SINGH R, BELL G S, et al. The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre[J]. Epilepsy Res, 2009, 87(2-3):120-123.
[24] SCHERNTHANER G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors[J]. Int J Clin Pract, 2009, 63(6):912-29.
[25] FILIPPATOS T D, KIORTSIS D N, LIBEROPOULOS E N, et al. A review of the metabolic effects of sibutramine[J]. Curr Med Res Opin, 2005, 21(3):457-466.
[26] DASKALOPOULOU S S, ATHYROS V G, ELISAF M, et al. Uric acid levels and vascular disease[J]. Curr Med Res Opin, 2004, 20(6):951-954.
[27] CHUANG Y C, CHUANG H Y, LIN T K, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis[J]. Epilepsia, 2012, 53(1):120-128.
[28] OZ O, GÖKÇIL Z, BEK S, et al. Is asymmetric dimethylarginine responsible for the vascular events in patients under antiepileptic drug treatment?[J]. Epilepsy Res, 2009, 87(1):54-58.
[29] AYCICEK A, ISCAN A. The effects of carbamazepine, valproic acid and phenobarbital on the oxidative and antioxidative balance in epileptic children[J]. Eur Neurol, 2007, 57(2):65-69.